Immunologic Mechanisms of Multiple Sclerosis

Neuroimaging Clinics of North America

Volumn 18, Issue 4, 2008, Pages 577-588

  Frohman, Elliot M ^a   Eagar, Todd ^a,b   Monson, Nancy ^a,b   Stuve, Olaf ^a,b   Karandikar, Nitin ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Macular volume; Multiple sclerosis; Optical coherence tomography; Pupillometry; Retinal nerve fiber layer

Indexed keywords

EPITOPE; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 5; INTERLEUKIN 6; OSTEOPONTIN; PROTEIN LINGO; PROTEIN NOGO; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

CD4 CD8 RATIO; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; ENVIRONMENTAL FACTOR; HEREDITY; HOMEOSTASIS; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNOPATHOLOGY; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE FIBER; NEUROPATHOLOGY; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; T CELL DEPLETION; TISSUE INJURY;

HUMANS; INFLAMMATION; LYMPHOCYTES; MULTIPLE SCLEROSIS; NERVE REGENERATION; SIGNAL TRANSDUCTION;

EID: 54949146492     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nic.2008.06.009     Document Type: Review

References (64)

1. Noseworthy J.H., Lucchinetti C., Rodriguez M., et al. Medical progress: multiple sclerosis. N Engl J Med 343 (2000) 938-952
2. Frohman E.M. Multiple sclerosis. Med Clin N Am 87 (2003) 867-897
3. Lublin F.D., Baier M., and Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 61 11 (2003) 1528-1532
4. Maeder R. Does the history of multiple sclerosis go back as far as the 14th century?. Acta Neurol Scand 60 (1979) 189-192
5. Charcot J.M. Histologie de la sclerose en plaques. Gaz Hop Civils Milit (Paris) 41 (1868) 554-558
6. Schumacher F.A., Beeve G.W., Kibler R.F., et al. Problems of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 122 (1965) 552-568
7. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13 (1983) 227-231
8. McDonald W.I., Compson A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50 (2001) 121-127
9. Polman C.H., Reingold S.C., Edan G., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol 58 6 (2005) 840-846 [review]
10. Frohman E.M., Goodin D., Calabresi P., et al. The utility of MRI in suspected MS. The Therapeutics and Technology Assessment Committee of the American Academy of Neurology. Neurology 61 (2003) 602-611
11. Comi G., Filippi M., Barkhof F., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 357 (2001) 1576-1582
12. Jacobs L.D., Beck R.W., Simon J.H., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343 (2000) 898-904
13. Kappos L., Freedman M.S., Polman C.H., et al., BENEFIT Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370 9585 (2007) 389-397
14. Rindfleisch E. Histologische detail zu der grauen degeneration von gehirn and ruckenmark. Virchow Arch Path Anat Physiol 26 (1863) 474-483
15. Frohman E.M., Raine C., and Racke M.K. Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med 354 (2006) 942-955
16. Lovett-Racke A.E., Trotter J.L., Lauber J., et al. Decreased dependence of myelin basic protein-reactive T cells on CD28 mediated costimulation in multiple sclerosis patients: a marker of activated memory T cells. J Clin Invest 101 (1998) 725-730
17. Scholz C., Patton K.T., Anderson D.E., et al. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J Immunol 160 (1998) 1532-1538
18. Moldavan I.R., Rudick R.A., Cotleur A.C., et al. Interferon gamma responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progression. J Neuroimmunol 141 (2003) 132-140
19. van Oosten B.W., Lai M., Hodgkinson S., et al. Treatment of multiple sclerosis with monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MRI-monitored phase II trial. Neurology 49 (1997) 351-357
20. Rep M.H., van Oosten B.W., Roos M.T., et al. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naïve T cells but does not affect IFN gamma secreting TH1 cells in humans. J Clin Invest 99 (1997) 2225-2231
21. Hori S., Nomura T., and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003) 1057-1061
22. Sakaguchi S., and Powrie F. Emerging challenges in regulatory T cell function and biology. Science 317 (2007) 627-629
23. Huan J., Culbertson N., Spencer L., et al. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 81 (2005) 45-52
24. Trapp B., Peterson J., Ransohoff R.M., et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338 (1998) 278-285
25. Lucchinetti C.F., Brueck W., Rodriquez M., et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 6 (1996) 259-274
26. Lucchinetti C.F., Brueck W., Rodruquez M., et al. Multiple sclerosis: lessons from neuropathology. Semin Neurol 18 (1998) 337-349
27. Babbe H., Roers A., Waisman A., et al. Clonal expansions of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192 (2000) 393-404
28. Crawford M.P., Yan S.X., Ortega S., et al. High prevalence of autoreactive neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 103 (2004) 4222-4231
29. Karandikar N.J., Crawford M.P., Yan X., et al. Glatiramer acetate (Copaxone) therapy induces CD8+ T cell responses in patients with multiple sclerosis. J Clin Invest 109 (2002) 641-649
30. Johnson K.P., Brooks M.D., Cohen J.A., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45 (1995) 1268-1276
31. Kabat E.A., Moore D.H., and Landow H. An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins. J Clin Invest 21 5 (1942) 571-577
32. Villar L.M., García-Barragán N., Sádaba M.C., et al. Accuracy of CSF and MRI criteria for dissemination in space in the diagnosis of multiple sclerosis. J Neurol Sci 266 1-2 (2008) 34-37
33. Levin M.C., Lee S.M., Kalume F., et al. Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat Med 8 (2002) 509-513
34. Nemazee D., and Hogquist K.A. Antigen receptor selection by editing or downregulation of V(D)J recombination. Curr Opin Immunol 15 (2003) 182-189
35. Owens G., Ritchie A., Burgoon M., et al. Single cell repertoire analysis demonstrates clonal expansion is prominent feature of the B cell response in multiple sclerosis spinal fluid. J Immunol 171 (2003) 2725-2733
36. Hauser S.L., Waubant E., Arnold D., et al. B cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358 (2008) 676-688
37. Lehmann P.V., Forsthuber T., Miller A., et al. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358 (1992) 155-157
38. Tian J., Gregori S., Adorini L., et al. The frequency of high avidity T cells determines the hierarchy of determinant spreading. J Immunol 166 (2001) 7144-7150
39. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8 (1998) 275-283
40. Balashov K.E., Smith D.R., Khoury S.J., et al. Increased IL-12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A 94 (1997) 599-603
41. Sharief M.K., and Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325 (1991) 467-472
42. Mosmann T.R., Cherwinski H., Bond M.W., et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136 (1986) 2348-2357
43. Comabella M., Balashov K., Issazadeh S., et al. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 102 (1998) 671-678
44. Seder R.A., and Paul W.E. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 12 (1994) 635-673
45. Langrish C.L., Chen Y., Blumanschein W.M., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201 (2005) 233-240
46. Panitch H.S., Hirsch R.L., Haley A.S., et al. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1 (1987) 893-895
47. Steimle V., Siegrist C.A., Mottet A., et al. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265 (1994) 106-109
48. Duda P.W., Schmied M.C., Cook S.L., et al. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 105 (2000) 967-976
49. Youssef S., Stuve O., Patarroyo J.C., et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420 (2002) 78-84
50. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6 (2005) 1123-1132
51. Polman C.H., O'Connor P.W., Havrdova E., et al., AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354 (2006) 899-910
52. Ransom B.R., Waxman S.G., and Davis P.K. Anoxic injury of CNS white matter: protective effect of ketamine. Neurology 40 (1990) 1399-1404
53. Stys P.K., Waxman S.G., and Ransom B.R. Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na_-Ca2_ exchanger. J Neurosci 12 (1992) 430-439
54. Craner M.J., Newcombe J., Black J.A., et al. Molecular changes in neurons in MS: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na_/C2_ exchanger in the human CNS. Proc Natl Acad Sci U S A 101 (2004) 8168-8173
55. Smith K.J., Kapoor R., Hall S.M., et al. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 49 (2001) 470-476
56. Kapoor R., Davies M., Blaker P.A., et al. Blockers of sodium and calcium entry protect axons from nitric oxide mediated degeneration. Ann Neurol 53 (2003) 174-180
57. Waxman S.G. NO and the axonal death cascade. Ann Neurol 53 (2003) 150-154
58. Domeniconi M., Cao Z., Spencer T., et al. Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Neuron 35 (2002) 283-290
59. Garcia-Merino A., Alper C.A., Usuku K., et al. Tumor necrosis factor microsatellite haplotypes in relation to extended haplotypes, susceptibility to diseases associated with the major histocompatibility complex, and TNF secretion. Hum Immunol 50 (1996) 11-21
60. Chabas D., Baranzini S., Mitchell D., et al. The influence of the pro-inflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294 (2001) 1731-1735
61. Lock C., Hermans G., Pedotti R., et al. Gene microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8 (2002) 500-508
62. Steinman L., and Zamvil S. Transcriptional analysis of targets in multiple sclerosis. Nat Rev Immunol 3 (2003) 483-493
63. Vogt M., Lopatinskaya L., Smits M., et al. Elevated osteopontin levels are associated with disease activity in relapsing-remitting MS patients. Ann Neurol 53 (2003) 819-822
64. International Multiple Sclerosis Genetics Consortium, Hafler D.A., Compston A., et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357 9 (2007) 851-862